奈西立肽对心力衰竭患者肾功能和死亡率的影响。

Impact of nesiritide on renal function and mortality in patients suffering from heart failure.

作者信息

Dontas Ioannis D, Xanthos Theodoros, Dontas Ismene, Lelovas Pavlos, Papadimitriou Lila

机构信息

Department of Experimental Surgery and Surgical Research N.S.Christeas, University of Athens, Medical School, Athens, Greece.

出版信息

Cardiovasc Drugs Ther. 2009 Jun;23(3):221-33. doi: 10.1007/s10557-009-6167-6.

DOI:10.1007/s10557-009-6167-6

PMID:19252976

Abstract

INTRODUCTION

Acutely decompensated congestive heart failure is a major public health problem, with constantly rising prevalence, morbidity, mortality and need for hospitalization in both America and Europe. In 2001, the FDA approved the use of the drug nesiritide, which is a recombinant form of human brain or B-type natriuretic peptide (BNP) for the treatment of acutely decompensated congestive heart failure. In 2005, suspicions arose that nesiritide may worsen renal function and increase the risk of short term mortality when given to patients with acutely decompensated heart failure.

METHODS

The present study reviews the recent literature with respect to the risk of deterioration in renal function and survival after the use of nesiritide in these patients.

RESULTS

Administration of nesiritide may be considered for the treatment of heart failure and especially in patients with dyspnea at rest or with minimal activity.

CONCLUSION

Extreme caution is required when using nesiritide in patients with both heart failure and concurrent morbidities such as renal dysfunction.

摘要

引言

急性失代偿性充血性心力衰竭是一个重大的公共卫生问题，在美国和欧洲，其患病率、发病率、死亡率以及住院需求都在持续上升。2001年，美国食品药品监督管理局（FDA）批准使用药物奈西立肽，它是一种重组形式的人脑利钠肽或B型利钠肽（BNP），用于治疗急性失代偿性充血性心力衰竭。2005年，有人怀疑，在给予急性失代偿性心力衰竭患者奈西立肽时，它可能会使肾功能恶化并增加短期死亡风险。